Asia-Pacific
While IP Australia’s updated manual could be favourable to computer-implemented inventions, stakeholders would like to see whether a consistent and reliable standard is followed during actual examination
Patent partner Robert Hollingshead explains why the firm remains committed to Japan despite several US firms exiting the Japanese and greater Asia market
The High Court of Australia has allowed a fashion designer to retain her registered ‘Katie Perry’ trademark for clothing
Sim & San secured the win for Dr. Reddy’s, which will allow the pharma company to manufacture and export semaglutide, the active ingredient in Ozempic
Sponsored
Sponsored
-
Sponsored by Bird & BirdSeiko Hidaka of Bird & Bird and Kento Sumi, currently seconded to Bird & Bird, analyse a landmark decision in a standard-essential patent case and its implications for licensing practices and future litigation in Japan -
Sponsored by Wanhuida Intellectual PropertyJicheng Yang of Wanhuida Intellectual Property considers whether a notable Beijing Intellectual Property Court decision signals a change to assessing inventive step in polymorph patents in China
-
Sponsored by Hechanova GroupEditha R Hechanova, Brenda P Rivera, and Maricris V Faderugao of Hechanova Group examine new trademark and patent representative rules aimed at professionalising intellectual property services and aligning with global standards
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Parth Bajaj of RNA, Technology and IP Attorneys consider the potential impact of two US cases on Indian jurisprudence and what constitutes fair use of copyrighted material in training AI models
-
Sponsored by Tilleke & GibbinsThe measures represent a ‘strategic leap’ for Vietnam’s intellectual property landscape, say Thuy Thi Ngoc Huynh and Yen Thi Hai Pham of T&G Law Firm LLC (TGVN), the local associate firm of Tilleke & Gibbins
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law analyses a ruling that clarifies the scope of patent infringement, territoriality limits, and research exemptions in a cross-border dispute over Pfizer’s pneumococcal vaccine
